Historical Valuation
Cellebrite DI Ltd (CLBT) is now in the Fair zone, suggesting that its current forward PE ratio of 33.90 is considered Fairly compared with the five-year average of 46.94. The fair price of Cellebrite DI Ltd (CLBT) is between 15.34 to 35.41 according to relative valuation methord.
Relative Value
Fair Zone
15.34-35.41
Current Price：18.36
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Cellebrite DI Ltd (CLBT) has a current Price-to-Book (P/B) ratio of 9.70. Compared to its 3-year average P/B ratio of 7.33 , the current P/B ratio is approximately 32.32% higher. Relative to its 5-year average P/B ratio of 4.68, the current P/B ratio is about 107.37% higher. Cellebrite DI Ltd (CLBT) has a Forward Free Cash Flow (FCF) yield of approximately 3.22%. Compared to its 3-year average FCF yield of 3.50%, the current FCF yield is approximately -8.07% lower. Relative to its 5-year average FCF yield of 3.58% , the current FCF yield is about -10.19% lower.
P/B
Median3y
7.33
Median5y
4.68
FCF Yield
Median3y
3.50
Median5y
3.58
Competitors Valuation Multiple
AI Analysis for CLBT
The average P/S ratio for CLBT competitors is 7.93, providing a benchmark for relative valuation. Cellebrite DI Ltd Corp (CLBT.O) exhibits a P/S ratio of 8.28, which is 4.4% above the industry average. Given its robust revenue growth of 17.94%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CLBT
1Y
3Y
5Y
Market capitalization of CLBT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CLBT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CLBT currently overvalued or undervalued?
Cellebrite DI Ltd (CLBT) is now in the Fair zone, suggesting that its current forward PE ratio of 33.90 is considered Fairly compared with the five-year average of 46.94. The fair price of Cellebrite DI Ltd (CLBT) is between 15.34 to 35.41 according to relative valuation methord.
What is Cellebrite DI Ltd (CLBT) fair value?
CLBT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cellebrite DI Ltd (CLBT) is between 15.34 to 35.41 according to relative valuation methord.
How does CLBT's valuation metrics compare to the industry average?
The average P/S ratio for CLBT's competitors is 7.93, providing a benchmark for relative valuation. Cellebrite DI Ltd Corp (CLBT) exhibits a P/S ratio of 8.28, which is 4.40% above the industry average. Given its robust revenue growth of 17.94%, this premium appears unsustainable.
What is the current P/B ratio for Cellebrite DI Ltd (CLBT) as of Jan 10 2026?
As of Jan 10 2026, Cellebrite DI Ltd (CLBT) has a P/B ratio of 9.70. This indicates that the market values CLBT at 9.70 times its book value.
What is the current FCF Yield for Cellebrite DI Ltd (CLBT) as of Jan 10 2026?
As of Jan 10 2026, Cellebrite DI Ltd (CLBT) has a FCF Yield of 3.22%. This means that for every dollar of Cellebrite DI Ltd’s market capitalization, the company generates 3.22 cents in free cash flow.
What is the current Forward P/E ratio for Cellebrite DI Ltd (CLBT) as of Jan 10 2026?
As of Jan 10 2026, Cellebrite DI Ltd (CLBT) has a Forward P/E ratio of 33.90. This means the market is willing to pay $33.90 for every dollar of Cellebrite DI Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cellebrite DI Ltd (CLBT) as of Jan 10 2026?
As of Jan 10 2026, Cellebrite DI Ltd (CLBT) has a Forward P/S ratio of 8.28. This means the market is valuing CLBT at $8.28 for every dollar of expected revenue over the next 12 months.